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Mitochondrial dynamicsThe objective of this study was to elucidate the effect of partial reduction of the mitochondrial ﬁssion protein,
dynamin-related protein 1 (Drp1) onmitochondrial activity and synaptic viability. Recent knockout studies of
Drp1 revealed that homozygote Drp1 knockout mice are embryonic lethal due to reduced mitochondrial ﬁs-
sion, and that this reduced ﬁssion leads to developmental defects in the brain. In contrast, heterozygote
Drp1 knockout mice appear to be normal in terms of lifespan, fertility, and viability, and phenotypically
these animals are not different from wild-type mice. However, the effects of partial Drp1 reduction on mito-
chondrial function and synaptic activity are not well understood. In the present study, we sought to character-
ize synaptic, dendritic andmitochondrial proteins, andmitochondrial function and GTPase enzymatic activity,
in Drp1 heterozygote knockout mice. Interestingly, we found no signiﬁcant changes in synaptic, dendritic, and
mitochondrial proteins in the Drp1 heterozygote knockout mice compared to the wild-type mice. Further, mi-
tochondrial function and GTPase enzymatic activity appeared to be normal. However, H2O2 and lipid peroxi-
dation levels were signiﬁcantly reduced in the Drp1 heterozygote knockout mice compared to the wild-type
mice. These ﬁndings suggest that partial Drp1 reduction does not affect mitochondrial and synaptic viability
and may have therapeutic use in treating patients with Alzheimer's disease and Huntington's disease.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Structural abnormalities in mitochondria have been reported to be
involved in mitochondrial dysfunction and oxidative stress in aging,
cancer, diabetes, obesity, cardiovascular diseases and in age-related neu-
rodegenerative diseases, such as Alzheimer's disease (AD), Huntington's
disease (HD), Parkinson's disease, and amyotrophic lateral sclerosis
[1–17]. These structural abnormalities are primarily caused by an imbal-
ance in highly conserved, GTPase genes that are essential for mitochon-
drial ﬁssion and fusion. Dynamin-related protein 1 (Drp1) is essential
for mitochondrial ﬁssion, and mitofusins 1 and 2 (Mfn1, Mfn2), and
optic atrophy 1 (Opa1) are involved in mitochondrial fusion [18–22].
In normal, healthy mammalian cells, such as neurons, ﬁssion and
fusion cells balance equally, resulting in the maintenance of mito-
chondrial dynamics and distribution. However, recent research has
found that neurons that express mutant proteins (e.g., amyloid beta
in AD and mutant huntingtin in HD) show impaired ﬁssion and fusion
balance [2,3,8–11,23,24]. This impaired balance is primarily due to the
abnormal interaction between Drp1 (a ﬁssion protein) and mutantOregon National Primate Re-
niversity, 505 NW 185th Ave-
; fax: +1 503 418 2701.
l rights reserved.proteins. These abnormal interactions increase in disease progression,
in AD and HD [8,9,11,24], ultimately creating structural abnormalities
and consequent dysfunction in mitochondria. Mitochondrial dysfunc-
tion ultimately inhibits the production of adenosine triphosphate
(ATP) and damages neurons [2,3,8–10,23,24]. Given this chain of re-
sponses triggered by the interaction of Drp1 and mutant huntingtin
(in HD) and amyloid beta (in AD) proteins, researchers have sug-
gested that ameans to inhibit this interactionmay provide a therapeu-
tic strategy to preventmitochondrial abnormalities and dysfunction in
AD and HD [20,25].
Drp1 is a highly, evolutionary conserved, large GTPase protein that
is critically involved in regulating structural features of mitochondria,
including their size, shape, distribution, and remodeling, and in main-
taining mitochondrial viability [18,20,22]. Further, Drp1 may also be
involved in mitochondrial division, mitochondrial distribution, perox-
isomal fragmentation, phosphorylation, ubiquitination, and SUMOyla-
tion [20,22]. Most importantly, Drp1 is critical in GTPase enzymatic
activity, which in turn is critical for mitochondrial division.
In studies aimed at elucidating the normal function of Drp1, re-
searchers found that Drp1 homozygote knockout mice (Drp1−/−)
have developmental abnormalities, particularly in the forebrain, and
they die, on average, shortly after embryonic days 11.5–12.5 [26,27].
Similarly, neural cell-speciﬁc (NS) Drp1−/− mice died shortly after
birth, from brain hypoplasia. Primary culture of the NS-Drp1−/−
Table 1
Summary of antibody dilutions and conditions used in the immunoblotting analysis of mitochondrial, synaptic and dendritic proteins.
Marker Primary antibody—species
and dilution
Purchased from company,
state
Secondary antibody,
dilution
Purchased from company,
city and state
Drp1 Rabbit polyclonal 1:500 Novus Biological, Littleton, CO Donkey anti-rabbit HRP 1:10,000 GE Healthcare Amersham, Piscataway, NJ
Fis1 Rabbit polyclonal 1:400 Protein Tech Group, Inc, Chicago, IL Donkey anti-rabbit HRP 1:10,000 GE Healthcare Amersham, Piscataway, NJ
Mfn1 Rabbit polyclonal 1:400 Santa Cruz Biotechnology, INC, Santa Cruz, CA Donkey anti-rabbit HRP 1:10,000 GE Healthcare Amersham, Piscataway, NJ
Mfn2 Rabbit Polyclonal 1:400 Abcam, Cambridge, MA Donkey anti-rabbit HRP 1:10,000 GE Healthcare Amersham, Piscataway, NJ
CypD Mouse monoclonal 1:500 EMD, Calobiochem Chemicals INC, Gibbstown, NJ Sheep anti-mouse HRP
1:8,000
GE Healthcare Amersham, Piscataway, NJ
Synaptophysin Mouse monoclonal 1:400 Millipore, Temecula, CA Sheep anti-mouse HRP
1:8,000
GE Healthcare Amersham, Piscataway, NJ
PSD95 Rabbit polyclonal 1:400 Abcam, Cambridge, MA Donkey anti-rabbit HRP 1:10,000 GE Healthcare Amersham, Piscataway, NJ
MAP2 Rabbit polyclonal 1:500 Millipore, Temecula, CA Donkey anti-rabbit HRP 1:10,000 GE Healthcare Amersham, Piscataway, NJ
B-actin Mouse monoclonal 1:500 Sigma-Aldrich, St Louis, MO Sheep anti-mouse HRP
1:10,000
GE Healthcare Amersham, Piscataway, NJ
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defective synapse formation, the latter which was suggested to due
to aggregated mitochondria that failed to distribute properly within
cell processes [27]. Wakabayashi et al. [26] found mitochondria
formed extensive networks, and peroxisomes were elongated in
Drp1−/− embryonic ﬁbroblasts. Brain-speciﬁc Drp1 depletion
resulted in the development of a few giant mitochondria instead of
many short, tubular mitochondria observed in control cells [26]. Over-
all, these results suggest that Drp1 is critical for mitochondrialmainte-
nance, division, and distribution in neurons.
In a diseased state, such as AD and HD, Drp1 has been found to in-
teract with mutant huntingtin and amyloid beta proteins, leading to
excessive mitochondrial fragmentation, mitochondrial dysfunction,
oxidative stress, and neuronal damage [8,9,11]. A key question is
how much Drp1 expression is sufﬁcient to inhibit the interaction be-
tweenDrp1 and themutant proteins, in order to prevent excessivemi-
tochondrial fragmentation—yet is sufﬁcient to balance mitochondrial
ﬁssion and fusion, and to maintain mitochondrial function and neuro-
nal survival in a diseased state? To address this issue, we characterized
Drp1+/− mice and Drp1+/+ mice for mitochondrial activity (mito-
chondrial proteins,mitochondrial function andGTPase Drp1 enzymat-
ic activity), and synaptic viability (synaptic and dendritic proteins).Table 2
Summary of antibody dilutions and conditions used in the immunohistochemistry/immuno
DRP+/+ and DRP+/− mouse.
Marker Primary antibody—species
and dilution
Purchased from company,
state
Drp1 Rabbit polyclonal 1:200 Santa Cruz Biotechnology, Inc,
Santa Cruz, CA
Fis1 Rabbit polyclonal 1:200 Santa Cruz Biotechnology, Inc,
Santa Cruz, CA
Mfn1 Rabbit polyclonal 1:200 Santa Cruz Biotechnology, Inc,
Santa Cruz, CA
Mfn2 Rabbit polyclonal 1:400 Abcam, Cambridge, MA
CypD Mouse monoclonal 1:500 EMD, Calobiochem Chemicals In
Gibbstown, NJ
Pyruvate dehydrogenase Mouse monoclonal 1:1000 Mitosciences Eugene, OR
Synaptophysin Mouse monoclonal 1:300 Millipore, Temecula, CA
PSD95 Rabbit polyclonal 1:400 Abcam, Cambridge, MA
MAP2 Rabbit polyclonal 1:400 Millipore, Temecula, CA2. Materials and methods
2.1. Drp1 mice and brain tissues
We used brain tissues Drp1 heterozygote knockout (Drp1+/−)
mice and control, wild-type (WT) Drp1+/+ [26] to determine the ef-
fects of partial Drp1 deﬁciency on mitochondrial dynamics and pro-
teins, and on synaptic processes. The Drp1+/+ and Drp1+/− mice
were housed at The Johns Hopkins University. The Johns Hopkins In-
stitutional Animal Care and Use Committee approved all procedures
for animal care. We genotyped all the mice for the Drp1 gene, using
DNA prepared from tail biopsies of 2–3 weeks old mice, following
the protocol described in Wakabayashi et al. [26].
2.2. Immunoblotting analysis
We performed immunoblotting analyses of protein lysates from 3-
month-old Drp1+/+ mice (n=3) and Drp1+/−mice (n=3). Twenty
microgram protein lysates were resolved on a 4–12% Nu-PAGE gel (Invi-
trogen, Grand Island, NY). These resolved proteins were transferred to
PVDF membranes (Novax Inc, San Diego, CA) and then incubated with
a blocking buffer (5% dry milk dissolved in a TBST buffer) for 1 h atﬂuorescence analysis of mitochondrial and synaptic proteins using brain sections from
Secondary antibody,
dilution, Alexa dye
Purchased from company,
city and state
Goat anti-rabbit Biotin 1:300, ABC,
TSA-Alexa488
KPL, Gaithersburg, MD
VECTOR Laboratories INC, Burlingame, CA
Molecular Probes, Eugene, OR
Goat anti-rabbit Biotin 1:300, ABC,
TSA-Alexa488
KPL, Gaithersburg, MD
VECTOR Laboratories INC, Burlingame, CA
Molecular Probes, Eugene, OR
Goat anti-rabbit Biotin 1:300, ABC,
TSA-Alexa488
KPL, Gaithersburg, MD
VECTOR Laboratories INC, Burlingame, CA
Molecular Probes, Eugene, OR
Goat anti - rabbit Biotin 1:300, ABC,
TSA-Alexa488
KPL, Gaithersburg, MD
VECTOR Laboratories INC, Burlingame, CA
Molecular Probes, Eugene, OR
c, Goat anti-mouse Biotin 1:300, ABC,
TSA-Alexa488
KPL, Gaithersburg, MD
VECTOR Laboratories INC, Burlingame, CA
Molecular Probes, Eugene, OR
Donkey anti-mouse Alexa 488 Molecular Probes, Eugene, OR
Goat anti-mouse Biotin 1:300, ABC,
TSA-Alexa488
KPL, Gaithersburg, MD
VECTOR Laboratories INC, Burlingame, CA
Molecular Probes, Eugene, OR
Goat anti-rabbit Biotin 1:300, ABC,
TSA-Alexa488
KPL, Gaithersburg, MD
VECTOR Laboratories INC, Burlingame, CA
Molecular Probes, Eugene, OR
Goat anti rabbit Biotin 1:300, ABC,
TSA-Alexa488
KPL, Gaithersburg, MD
VECTOR Laboratories INC, Burlingame, CA
Molecular Probes, Eugene, OR
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with primary Drp1 antibodies (1:200 rabbit polyclonal Novus Biological
Inc, Littleton, CO), Fis1 (1:200 dilution, Protein Tech Group Inc, Chicago,
IL), Mfn1 (1:300 rabbit polyclonal, Santa Cruz Biotechnology Inc, Santa
Cruz, CA), Mfn2 (1:300 rabbit polyclonal, Abcam, Cambridge, MA),
Opa1 (1:500 mouse-monoclonal, BD Biosciences, San Jose, CA), CypD
(1:500 mouse monoclonal, EMD Calbiochem, Gibbstown, NJ), synapto-
physin (1:400 mouse monoclonal, Millipore, Temecula, CA ), PSD95
(1:400 rabbit polyclonal, Abcam), MAP2 (1:500 rabbit polyclonal, Milli-
pore) and β-actin (1:500 mouse monoclonal Chemicon, Millipore with
Sigma-Aldrich, St. Louis, MO).
Themembranes werewashedwith a TBST buffer 3 times at 10-min
intervals and then incubated for 2 h with appropriate secondary anti-
bodies, followed by 3 additional washes at 10-min intervals. Details of
secondary antibodies and their dilutions are given Table 1. Mitochon-
drial, synaptic and dendritic proteins were detected with the Super-
signal West Pico chemiluminescent reagent (Thermo Scientiﬁc).
Scanned images of the exposed X-ray ﬁlm were analyzed with ImageJ
to determine relative band intensity. Quantiﬁcationwas performed on
western blots of cerebral cortex and cerebellum protein lysates from
Drp1+/+ mice and Drp1+/−mice.
2.3. Immunohistochemistry and immunoﬂuorescence analyses
Using immunoﬂuorescence techniques, we performed immunos-
taining for synaptophysin and PSD95 (synaptic proteins), MAP2Fig. 1. Immunoblotting analysis of mitochondrial proteins. A represents representative imm
grams of protein lysate was used from cerebral cortex and cerebellum tissues from the Drp1
Mfn1, Mfn2, CypD, and beta actin, as a control for equal loading protein. B represents quan(dendritic protein), Drp1, Fis1 (ﬁssion proteins), Mfn1, Mfn2 (fusion
protein), and CypD (matrix protein) in brain sections we excised
from Drp1+/+ mice and Drp1+/− mice. The brain specimens were
embedded parafﬁn, and sections were cut into widths of 15 μm. The
sections were deparafﬁnized by a 10-min wash with xylene, followed
by a 5-min wash in each of 3 serial dilutions of alcohol (at 95, 70, and
50%). The sections were again washed once for 10 min, with double-
distilled H2O, and then for 6 more times with phosphate-buffered sa-
line (PBS) at pH 7.4, at 5 min each. To block the endogenous peroxi-
dase, sections were treated for 15 min with 3% H2O2 and then with
0.5% Triton dissolved in PBS at pH 7.4. The sections were blocked for
1 h with a solution of 0.5% Triton in PBS+10% goat serum+1% bo-
vine serum albumin.
The sections were incubated overnight at room temperature with
the following antibodies: anti-Drp1 (1:200 rabbit polyclonal dilution,
Santa Cruz Biotechnology), Fis1 (1:200 dilution, Protein Tech Group
Inc), Mfn1 (1:200 rabbit polyclonal Santa Cruz Biotechnology Inc),
Mfn2 (1:400 rabbit polyclonal, Abcam), Opa1 (1:500 mouse-
monoclonal BD Biosciences), CypD (1:500 mouse monoclonal,
EMD Calbiochem), pyruvate dehyrogenase (1:1000, Mitosciences,
Eugene, OR), synaptophysin (1:400 mouse monoclonal, Millipore),
PSD95 (1:400 rabbit polyclonal, Abcam) and MAP2 (1:500, rabbit
polyclonal, Millipore).
On the day after the primary antibody incubation, sections were
washed once with 0.1% Triton in PBS and were then incubated with
appropriate biotinylated secondary antibodies for 1 h at roomunoblots of mitochondrial proteins in Drp1+/+ mice and Drp1+/−mice. Fifty micro-
+/+ and Drp1+/−mice. Immunoblotting analyses were performed, using Drp1, Fis1,
titative densitometric analysis of mitochondrial proteins.
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given in Table 2. The sections were washed with PBS 3 times for
10 min each and then incubated for 1 h with labeled streptavidin,
an HRP solution (Molecular Probes, Eugene, OR). The sections were
each washed 3 more times for 10 min each, with PBS at pH 7.4,
and then were treated with Tyramide Alexa 594 (red) or Alexa
488 (green) (Molecular Probes) for 10 min at room temperature.
They were cover-slipped with Prolong Gold (Invitrogen) and photo-
graphed with a confocal microscope. Randomly selected immunoﬂu-
orescence images from cerebral cortex sections of Drp1+/+ mice
and Drp1+/− mice at 40× magniﬁcation were analyzed with ImageJ
to determine relative immunoﬂuorescence intensity between Drp1+/+
mice and Drp1+/−mice for mitochondrial, synaptic and dendritic pro-
teins. To determine mitochondrial morphology, we photographed the
hippocampal and cerebral cortex sections from Drp1+/+ (WT) and
Drp1+/− mice that were immunostained with mitochondrial matrix
marker, pyruvate dehydrogenase.
3. Mitochondrial function
3.1. H2O2 production
Using an Amplex® Red H2O2 Assay Kit (Molecular Probes), wemea-
sured the production of H2O2 in the tissues from the cerebral cortex and
the cerebellum of Drp1+/− mice (n=3) and Drp1+/+ mice (n=3),
as previously described [28]. Brieﬂy, the production of H2O2 was mea-
sured inmitochondria isolated from cerebral cortex and the cerebellum
of Drp1+/−mice and Drp1+/+mice. A BCA Protein Assay Kit (Pierce
Biotechnology) was used to measure protein concentration in a reac-
tion mixture that contained mitochondrial proteins (μg/μl), Amplex
Red reagents (50 μM), horseradish peroxidase (0.1 U/ml), and a reac-
tion buffer (1×). The mixture was incubated at room temperature for
30 min, followed by spectrophotometer readings of ﬂuorescence
(570 nm). Finally, H2O2 production was determined, using a standard
curve equation expressed in nmol/μg mitochondrial protein.Fig. 2. Immunoblotting analysis of synaptic and dendritic proteins. A represents representa
mice. Fifty micrograms of protein lysate was used from cerebral cortex and cerebellum tissu
using synaptophysin, PSD95, MAP2, and beta actin, as a control for equal loading protein. B3.2. Cytochrome oxidase activity
Cytochrome oxidase activity was measured in mitochondria isolat-
ed from the cerebral cortex and cerebellum of Drp1+/− mice (n=3)
and Drp1+/+ mice (n=3), as described in Manczak et al. [23]. En-
zyme activity was assayed spectrophotometrically with a Sigma Kit
(Sigma-Aldrich) followingmanufacturer's instructions. Brieﬂy, 2 μg mi-
tochondrial protein was added to 1.1 ml of a reaction solution contain-
ing 50 μl 0.22 mM ferricytochrome c fully reduced by DTT, Tris–HCl at
pH 7.0, and 120 mMpotassium chloride. The absorbance of wavelength
at 550 mM (or its decrease) was recorded in 1-min reactions, at 10-s
intervals. Cytochrome c oxidase activity was measured according to
the following formula: mU/mg total mitochondrial protein=(A/min
sample−(A/min blank)×1.1 mL×21.84). The protein concentrations
were determined, following the BCA method.
3.3. ATP levels
The levels of ATP were measured in mitochondria that were isolat-
ed from cerebral cortex and cerebellum tissues of Drp1+/− mice
(n=3) and Drp1+/+ mice (n=3), with a ATP determination kit
(Molecular Probes) [29]. This bioluminescence assay is based on the
reaction of ATPwith recombinant ﬁreﬂy luciferase and its substract lu-
ciferin. Luciferase catalyzes the formation of light from ATP and lucif-
erin. It is the emitted light that is linearly related to the ATP
concentration, which is measured using a luminometer. Wemeasured
ATP from mitochondrial pellets, using a standard curve method.
3.4. Lipid peroxidation assay
Lipid peroxidates are unstable indicators of oxidative stress in
neurons [30]. 4-hydroxy-2-nonenol (HNE) is the ﬁnal product of
lipid peroxidation that was measured in cerebral cortex and cerebel-
lum tissues of Drp1+/− mice (n=3) and Drp1+/+ mice (n=3),
with an HNE-His ELISA Kit (Cell BioLabs, Inc., San Diego, CA). Brieﬂy,tive immunoblots of synaptic and dendritic proteins in Drp1+/+ mice and Drp1+/−
es from the Drp1+/+ and Drp1+/− mice. Immunoblotting analyses were performed,
represents quantitative densitometric analysis of synaptic and dendritic proteins.
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and incubated overnight at 4 °C. It was then washed 3 times with a
wash buffer. The washed protein and the anti-HNE-His antibody
were then added to wells and incubated for 2 h at room temperature,
and then washed 3 times. Next, the samples were incubated with a
secondary antibody that was conjugated with peroxidase for 2 h at
room temperature. They were then incubated with an enzyme sub-
strate. Optical density was measured to quantify the level of HNE
(lipid peroxidation).
3.5. GTPase enzymatic activity
Using a Novus Biological calorimetric kit (Littleton, CO), wemeasured
GTPase enzymatic activity in cerebral cortex and cerebellum tissues from
Drp1+/+ mice (n=3) and Drp1+/− mice (n=3), following GTPase
assaymethods described in Shirendeb et al. [11], based on GTP hydrolyz-
ing to GDP and to inorganic phosphorous (Pi). We measured GTPase ac-
tivity, based on the amount of Pi that the GTP produces. By adding the
ColorLock Gold (orange) substrate to the Pi generated from GTP, weFig. 3. Immunoreactivity of Drp1 in brain sections from Drp1+/+ mice and Drp1+/− mic
cortex (10× the original magniﬁcation); (C), the cerebral cortex (40× the original magniﬁcassessed GTP activity, based on the inorganic complex solution (green).
Calorimetric measurements (green) were read in the wavelength range
of 650 nm.We compared GTPase activity in cereberal cortex and cerebel-
lum tissues from the Drp1+/−mice and the Drp1+/+mice.
4. Results
4.1. Immunoblotting analysis
To determine the effects of partial Drp1 deﬁciency on mitochon-
drial proteins (Drp1, Fis1, Mfn1, Mfn2, Opa1, and CypD), on synaptic
proteins (synaptophysin and PSD95), and on dendritic proteins
(MAP2), mitochondrial, synaptic, and dendritic proteins were mea-
sured in cerebral cortex and cerebellum tissues from Drp1 +/−
mice and Drp1+/+ mice.
4.1.1. Mitochondrial proteins
As shown in Fig. 1A and B, we found reduced levels of Drp1 in the
cerebral cortex (P=0.2) and cerebellum (P=0.06) tissues from thee. (A) represents the hippocampus (10× the original magniﬁcation); (B), the cerebral
ation) and (D) quantiﬁcation of Drp1 immunoreactivity in the cerebral cortex.
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were not signiﬁcantly different, indicating only partial Drp1 reduction
in the brain tissues from the Drp1+/− mice. However, we did not
ﬁnd reduced levels of Fis1 in the cerebral cortex (P=0.9) and cere-
bellum (P=0.1) tissues from the Drp1+/− mice and the Drp1+/+
mice, respectively (Fig. 1A and B). We also did not ﬁnd any signiﬁcant re-
duction in theMfn1 levels in the cerebral cortex (P=0.8) and cerebellum
(P=0.1) tissues from the Drp1+/− mice and the Drp1+/+ mice, re-
spectively. Similar results were found for Mfn2 and CypD (Fig. 1A and B).Fig. 4. Immunoreactivity of Fis1 in brain sections from Drp1+/+mice and Drp1+/−mice. (
tex (10× the original magniﬁcation); (C), the cerebral cortex (40× the original magniﬁcati4.1.2. Synaptic and dendritic proteins
Our quantitative immunoblotting analysis of synaptophysin and
PSD95 revealed no signiﬁcant changes in the cerebral cortex (P=0.9
for synaptophysin and P=0.7 for PSD95) and cerebellum (P=0.1 for
synaptophysin and P=0.9 for PSD95) tissues from in Drp1+/− mice
and Drp1+/+ mice (Fig. 2A and B). Dendritic protein, MAP2 was re-
duced in the cerebellum of Drp1+/− mice relative to Drp1+/+ mice
but not signiﬁcant (P=0.06). However, MAP2 levels were unchanged
between Drp1+/+ mice and Drp1+/−mice.A) represents the hippocampus (10× the original magniﬁcation); (B), the cerebral cor-
on) and (D) quantiﬁcation of Fis1 immunoreactivity in the cerebral cortex.
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To determine whether partial Drp1 deﬁciency affects the localization
and distribution of mitochondrial, synaptic, and dendritic proteins, we
conducted immunohistochemistry and immunoﬂuorescence analyses
of Drp1, Fis1, Mfn1, CypD, synaptic (synaptophysin and PSD95), and
dendritic (MAP2) proteins in brain tissues from Drp1+/− mice and
Drp1+/+mice.Wequantiﬁed the immunoreactivities of all the proteins.
4.2.1. Mitochondrial proteins
We found Drp1 to be ubiquitous in the hippocampus and cerebral
cortex tissues from both the Drp1+/− mice and Drp1+/+ mice, and
we found Drp1 to be reduced in the cerebral cortex sections from
Drp1+/− mice relative to Drp1+/+ mice, but not signiﬁcant
(P=0.06) (Fig. 3). As shown in Fig. 4, similar to Drp1, Fis1was uniform-
ly expressed in the brain. However, immunoreactivity of Fis1 was not
signiﬁcantly decreased in the cerebral cortex of the Drp1+/−mice rel-
ative to Drp1+/+ mice (P=0.06).
We did not ﬁnd any change in the immunoreactivity of mitochon-
drial fusion protein, Mfn1 (P=0.6) in the cerebral cortex brain sec-
tions from the Drp1+/− mice relative to Drp1+/+ mice,
suggesting that reduced expression Drp1 did not affect mitochondrial
fusion proteins in the brain (Fig. 5).Fig. 5. Immunoreactivity of Mfn1 in brain sections from Drp1+/+mice and Drp1+/−mice
the original magniﬁcation) and (C) quantiﬁcation of Mfn1 immunoreactivity in the cerebraSimilar to the fusion proteins, matrix protein, CypD immunoreac-
tivity was unchanged in the brain sections from the Drp1+/− and
Drp1+/+ mice (Fig. 6) (P=0.4).
4.2.2. Synaptic and dendritic proteins
Our quantitative immunohistochemistry analyses of synaptic
proteins revealed that immunoreactivities of synaptophysin
(Pb0.16) (Fig. 7) and PSD95 (Pb0.29) (Fig. 8) were unchanged
in the brain sections from the Drp1+/− and Drp1+/+ mice.
These results indicate that a partial reduction in Drp1 does affect
the expression of synaptic proteins. Similar to the immunoreactiv-
ity of synaptic proteins, the immunoreactivity of MAP2 did not
change between the Drp1+/− and Drp1+/+ mice (Fig. 9)
(P=0.11).
4.2.3. Mitochondrial network
To determine mitochondrial network, we immunostained the hip-
pocampal and cortical sections from Drp1+/+ and Drp1+/− mice
using mitochondrial matrix marker, pyruvate dehydrogenase. As
shown in Fig. 10, we did not ﬁnd increased mitochondrial network in
cerebral cortex regions from Drp1+/− mice relative to Drp1+/+
mice. However, we observed increased mitochondrial network in hip-
pocampal neurons of Drp1+/− mice relative to Drp1+/+ mice.. (A) the cerebral cortex (10× the original magniﬁcation); (B), the cerebral cortex (40×
l cortex.
Fig. 6. Immunoreactivity of cyclophilin D in brain sections from Drp1+/+ mice and Drp1+/− mice. (A) represents the hippocampus (10× the original magniﬁcation); (B), the
cerebral cortex (10× the original magniﬁcation); (C), the cerebral cortex (40× the original magniﬁcation) and (D) quantiﬁcation of CypD immunoreactivity in the cerebral cortex.
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To determine whether partial deﬁciency of Drp1 expression affects
mitochondrial function in Drp1/− mice, we characterized mitochon-
drial function by measuring H2O2 production, cytochrome oxidase ac-
tivity, lipid peroxidation, and ATP production in cerebral cortex and
cerebellum tissues from Drp1+/− mice and Drp1+/+ mice.
4.3.1. H2O2 production
Signiﬁcantly decreased levels of H2O2 were found in cerebral cor-
tex tissues from Drp1+/−mice relative to Drp1 +/+mice (P=0.04)
(Fig. 11). However, H2O2 levels were unchanged in the cerebellum of
Drp1+/− mice relative to Drp1 +/+ mice. These ﬁndings suggestthat partial reduction of Drp1 expression inﬂuences H2O2 levels in
the cortex but not in the cerebellum.
4.3.2. Cytochrome oxidase activity
Cytochrome oxidase activity, an indicator of complex IV of oxidative
phosphorylation, was unchanged in the cerebral cortex (P=0.2) and
cerebellum (P=0.07) from Drp1+/− mice relative to Drp1 +/+
mice (Fig. 11), indicating that a partial reduction of Drp1 did not alter
cytochrome c oxidase activity.
4.3.3. ATP production
Similar to cytochrome oxidase activity, we did not observe any
change in the level of ATP level for the cerebral cortex (P=0.6) and
Fig. 7. Immunoreactivity of synaptophysin in brain sections from Drp1+/+ mice and Drp1+/− mice. (A) represents the hippocampus (10× the original magniﬁcation); (B), the
cerebral cortex (10× the original magniﬁcation); (C), the cerebral cortex (40× the original magniﬁcation) and quantiﬁcation of synaptophysin immunoreactivity in the cerebral
cortex.
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spectively (Fig. 11).
4.3.4. Lipid peroxidation
We found signiﬁcantly reduced levels of lipid peroxidation in the ce-
rebral cortex tissues from the Drp1+/−mice relative to the Drp1+/+
mice (P=0.03) (Fig. 11). However, the levels were unchanged in the
cerebellum tissues from the Drp1+/− and Drp1+/+mice (P=0.51).
4.3.5. GTPase enzymatic activity
As shown in Fig. 12, GTPase Drp1 enzymatic activity was reduced
in cerebral cortex tissue from both the Drp1+/− and Drp1+/+mice,but not signiﬁcantly reduced (P=0.10) (Fig. 12). GTPase Drp1 enzy-
matic activity was unchanged in cerebellum tissue from the Drp1+/−
and Drp1+/+mice (P=0.9). These ﬁndings suggest that partial reduc-
tion of Drp1 does not affect GTPase Drp1 enzymatic activity.
5. Discussion
The objective of this study is to characterize mitochondrial, synap-
tic and dendritic proteins and mitochondrial function in Drp1 hetero-
zygote knockout (Drp1+/−) mice. The Drp1+/− mice that express
partial reduction of Drp1 are normal in terms of lifespan, fertility,
and viability [26], and phenotypically these mice are similar to WT
Fig. 8. Immunoreactivity of PSD95 in brain sections from Drp1+/+ mice and Drp1+/− mice. (A) represents the hippocampus (10× the original magniﬁcation); (B), the cerebral
cortex (10× the original magniﬁcation); (C), the cerebral cortex (40× the original magniﬁcation) and (D) quantiﬁcation of MAP2 immunoreactivity in the cerebral cortex.
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cause homozygote Drp1 knockout (or Drp1−/−) mice are embryonic
lethal with reduced mitochondrial ﬁssion, leading to developmental
and synaptic defects in the brain, and however, it was unclear, if syn-
aptic and mitochondrial deﬁciencies are present in Drp1+/−mice. In
the present study, we found no signiﬁcant changes in mitochondrial,
synaptic, and dendritic proteins in the Drp1+/−mice. Further, mito-
chondrial function and GTPase Drp1 enzymatic activity appeared to
be normal in these mice. However, H2O2 and lipid peroxidation levels
were signiﬁcantly reduced in Drp1+/− mice compared to control,
WT mice. Since synaptic and mitochondrial proteins were normal
and lipid peroxidation and H2O2 were reduced, these ﬁndings impli-
cate that partial reduction of Drp1 is expected to reduce excessive mi-
tochondrial fragmentation, maintain mitochondrial, and synaptic
functions in neurons, in diseased states, such as AD and HD.5.1. Mitochondrial function in Drp1 heterozygote knockout mice
Mitochondrial cytochrome oxidase activity and ATP production
were normal in the brain tissues from the Drp1+/−mice that we stud-
ied. However, lipid peroxidation and H2O2 levels were signiﬁcantly re-
duced, compared to WT mice. The reduction in H2O2 may be related
to partial deﬁciency of Drp1 since reduced Drp1 expression has been as-
sociated with a reduction in mitochondrial fragmentation, in turn possi-
bly leading to decreased H2O2 production and lower lipid peroxidation
that we found in the brain tissues from the Drp1+/− mice.
In AD and HD (and other neurodegenerative diseases), increased
production of free radicals and lipid peroxidation have been identi-
ﬁed as early changes in the diseased state, followed by altered mito-
chondrial enzyme activities and reduced ATP levels and neuronal
damage. These abnormalities in mitochondrial function have been
Fig. 9. Immunoreactivity of MAP2 in brain sections from Drp1+/+mice and Drp1+/−mice. (A) the cerebral cortex (10× the original magniﬁcation); (B) the cerebral cortex (40×
the original magniﬁcation) and (C) quantiﬁcation of MAP2 immunoreactivity in the cerebral cortex.
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these changes may occur primarily due to the abnormal interaction
between mutant huntingtin and amyloid beta protein(s) and Drp1.
Several recent reports support this notion in AD and HD [8,9,11,24].
In studies of mitochondria and amyloid beta in AD, researchers have
found that amyloid beta interacts with Drp1 in an age and disease
progression-dependent manner, induces elevated production of
GTPase Drp1 enzymatic activity, and causes excessive mitochondrial
fragmentation andmitochondrial dysfunction [8,24]. In investigations
of mitochondria and mutant huntingtin in HD, two recent studies
found that mutant huntingtin interacts with Drp1 mainly in disease-
affected neurons [9,11], and this interaction increased as the disease
progressed. They also found Drp1 interaction is polyQ repeat number
in disease progression. These studies suggest that mutant huntingtin
and amyloid beta proteins interact with Drp1, causing both structural
and functional changes in mitochondria in AD and HD. These studies
also implicate the reduction of amyloid beta and mutant huntingtin
may reduce Drp1 interaction and decrease mitochondrial fragmenta-
tion that reduced production of either mutant proteins or Drp1 or
both mutant proteins and Drp1 may protect affected neurons from
AD and HD. The present ﬁndings of reduced H2O2 and lipid peroxida-
tion in Drp1+/−mice support the implication that partial deﬁciency
of Drp1 may reduce mitochondrial structural and functional effects in
a disease state.5.2. Mitochondrial, synaptic, and dendritic proteins in heterozygote Drp1
knockout mice
Possible factors for the embryonic lethality of homozygote Drp1
knockout mice are developmental and synaptic defects that may be
primarily caused by reduced mitochondrial ﬁssion and elevated mito-
chondrial fusion in the axonal tracts of embryonic cells [26,27]. In con-
trast to the homozygote knockouts, the heterozygote Drp1 knockouts
(Drp1+/−mice) are normal and viable. However, there have been no
published reports of investigations into synapses and mitochondria.
Our study is the ﬁrst to investigate mitochondria activity and synaptic
viability, and we have found no signiﬁcant alterations in mitochondri-
al, synaptic, or dendritic proteins in the cerebral cortex and cerebel-
lum tissues from the Drp1+/− mice. Partial reduction of Drp1 did
not alter mitochondrial ﬁssion (Drp1, FIs1), fusion (Mfn1, Mfn2), or
matrix proteins (CypD). Further, quantitative analyses of key synaptic
and dendritic proteins – synaptophysin, PSD95, and MAP2 – were in-
tact in the Drp1+/− mice, conﬁrming that partial reduction of Drp1
may not be harmful to nondiseased neurons. Further research into
the role of partial Drp1 deﬁciency in a diseased state, such as AD and
HD, is still needed, to evaluate the extent of reduction that Drp1 can
protect synaptic or neuronal damage in the presence of amyloid beta
andmutant huntingtin. Therefore, Drp1+/−mice remain good candi-
dates to study partial Drp1 deﬁciency in a diseased state.
Fig. 10. Immunoreactivity of mitochondrial matrix marker, pyruvate dehydrogenase from Drp1+/+ and Drp1+/− mice. (A) represents hippocampal section 9100× the original
magniﬁcation) and (B) represents cerebral cortex (100× the original magniﬁcation. White arrows indicate elongated mitochondria.
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atedwith synaptic damage, neurodegeneration and clinical symptoms
found in AD and HD patients [31–36]. Other neurodegenerativeFig. 11. Mitochondrial functional parameters in Drp1+/+ mice and Drp1+/− mice. (A) re
mice and Drp1+/+ mice. Signiﬁcantly reduced hydrogen peroxide production was found in
resents cytochrome oxidase activity. Cytochrome oxidase activity was unchanged in the cer
(C) represents lipid peroxidation in cerebral cortex and cerebellum tissues from Drp1+/−
the cerebral cortex of Drp1+/−mice compared to Drp1+/+ mice (Pb0.05). (D) represents
the cerebral cortex and cerebellum tissues from Drp1+/− mice compared to Drp1+/+ midiseases, such as ALS, PD, and ataxias, may also be associatedwith syn-
aptic damage and neurodegeneration. The increased production of de-
fective mitochondria following the interaction of Drp1 and particularpresents hydrogen peroxide in cerebral cortex and cerebellum tissues from Drp1+/−
the cerebral cortex of Drp1+/− mice compared to Drp1+/+ mice (Pb0.05). (B) rep-
ebral cortex and cerebellum tissues from Drp1+/− mice compared to Drp1+/+ mice.
mice and Drp1+/+ mice. Signiﬁcantly reduced lipid peroxidation levels were found in
synaptosomal mitochondrial ATP. Synaptosomal mitochondrial ATP was unchanged in
ce.
Fig. 12. GTPase enzymatic activity inDrp1+/+mice andDrp1+/−mice. GTPase enzymat-
ic activity was unchanged in the cerebral cortex and cerebellum tissues from Drp1+/−
mice compared to Drp1+/+mice.
874 M. Manczak et al. / Biochimica et Biophysica Acta 1822 (2012) 862–874mutant proteins (e.g., amyloid beta, mutant huntingtin, mutant SOD1,
mutant PD proteins, and mutant ataxins) may lead to the inability of
mitochondria to transport to axons, dendrites, and terminals of neu-
rons and may lead to the inability of mitochondria to produce sufﬁ-
cient quantities of ATP at synapses. These mitochondrial impairments
may induce synaptic damage, and neurodegeneration, and may ulti-
mately lead to clinical symptoms seen in AD and PD patients.
In summary, we found that Drp1+/− mice (Drp1 heterozygote
mice) do not have mitochondrial and synaptic deﬁciencies and, fur-
ther, that these mice show reduced oxidative stress (levels of H2O2
and lipid peroxidation). Thus, Drp1+/− mice are excellent candi-
dates for further studies of partial Drp1 deﬁciency in mitochondrial
structure and mitochondrial function, and in deﬁciencies in synaptic
viability in AD and HD.
Acknowledgements
This research was supported by NIH grants AG028072, RR000163
(to PHR) and GM089853 (HS) and Alzheimer Association grant
IIRG-09-92429 (to PHR).
References
[1] R.H. Swerdlow, The neurodegenerative mitochondriopathies, J. Alzheimers Dis.
17 (2009) 737–751.
[2] X. Wang, B. Su, S.L. Siedlak, P.I. Moreira, H. Fujioka, Y. Wang, G. Casadesus, X. Zhu,
Amyloid-beta overproduction causes abnormal mitochondrial dynamics via dif-
ferential modulation of mitochondrial ﬁssion/fusion proteins, Proc. Natl. Acad.
Sci. U. S. A. 105 (2008) 19318–19323.
[3] X. Wang, B. Su, H.G. Lee, X. Li, G. Perry, M.A. Smith, X. Zhu, Impaired balance of mi-
tochondrial ﬁssion and fusion in Alzheimer's disease, J. Neurosci. 29 (2009)
9090–9103.
[4] H. Du, L. Guo, F. Fang, D. Chen, A.A. Sosunov, G.M. McKhann, Y. Yan, C. Wang, H.
Zhang, J.D. Molkentin, F.J. Gunn-Moore, J.P. Vonsattel, O. Arancio, J.X. Chen, S.D.
Yan, Cyclophilin D deﬁciency attenuates mitochondrial and neuronal perturba-
tion and ameliorates learning and memory in Alzheimer's disease, Nat. Med. 14
(2008) 1097–1105.
[5] H. Du, L. Guo, S. Yan, A.A. Sosunov, G.M. McKhann, S.S. Yan, Early deﬁcits in syn-
aptic mitochondria in an Alzheimer's disease mouse model, Proc. Natl. Acad. Sci.
U. S. A. 107 (2010) 18670–18675.
[6] M.T. Lin, M.F. Beal, Mitochondrial dysfunction and oxidative stress in neurode-
generative diseases, Nature 443 (2006) 787–795.
[7] D.T. Chang, I.J. Reynolds, Mitochondrial trafﬁcking and morphology in healthy
and injured neurons, Prog. Neurobiol. 80 (2006) 241–268.
[8] M. Manczak, M.J. Calkins, P.H. Reddy, Impaired mitochondrial dynamics and ab-
normal interaction of amyloid beta with mitochondrial protein Drp1 in neurons
from patients with Alzheimer's disease: implications for neuronal damage,
Hum. Mol. Genet. 20 (2011) 2495–2509.
[9] W. Song, J. Chen, A. Petrilli, G. Liot, E. Klinglmayr, Y. Zhou, P. Poquiz, J. Tjong, M.A.
Pouladi, M.R. Hayden, E. Masliah, M. Ellisman, I. Rouiller, R. Schwarzenbacher, B.
Bossy, G. Perkins, E. Bossy-Wetzel, Mutant huntingtin binds the mitochondrial
ﬁssion GTPase dynamin-related protein-1 and increases its enzymatic activity,
Nat. Med. 17 (2011) 377–382.[10] U. Shirendeb, A.P. Reddy, M. Manczak, M.J. Calkins, P. Mao, D.A. Tagle, P.H. Reddy,
PH. Abnormal mitochondrial dynamics, mitochondrial loss and mutant hunting-
tin oligomers in Huntington's disease: implications for selective neuronal dam-
age, Hum. Mol. Genet. 20 (2011) 1438–1455.
[11] U.P. Shirendeb, M.J. Calkins, M. Manczak, V. Anekonda, B. Dufour, J.L. McBride, P.
Mao, P.H. Reddy, Mutant huntingtin's interaction with mitochondrial protein
Drp1 impairs mitochondrial biogenesis and causes defective axonal transport
and synaptic degeneration in Huntington's disease, Hum. Mol. Genet. 21 (2012)
406–420.
[12] J. Kuzmicic, A. Del Campo, C. Lopez-Crisosto, P.E. Morales, C. Pennanen, R. Bravo-
Sagua, J. Hechenleitner, R. Zepeda, P.F. Castro, H.E. Verdejo, V. Parra, M. Chiong, S.
Lavandero, Mitochondrial dynamics: a potential new therapeutic target for heart
failure, Rev. Esp. Cardiol. 64 (2011) 916–923.
[13] D.M. Krzywanski, D.R. Moellering, J.L. Fetterman, K.J. Dunham-Snary, M.J. Sammy,
S.W. Ballinger, The mitochondrial paradigm for cardiovascular disease suscepti-
bility and cellular function: a complementary concept to Mendelian genetics,
Lab. Invest. 91 (2011) 1122–1135.
[14] A.K. Camara, M. Bienengraeber, D.F. Stowe, Mitochondrial approaches to protect
against cardiac ischemia and reperfusion injury, Front. Physiol. 2 (2011) 13.
[15] D.C. Wallace, Bioenergetic Origins of Complexity and Disease, Cold Spring Harb.
Symp. Quant. Biol. (Dec 22 2011) [Epub ahead of print].
[16] C.C. Cook, M. Higuchi, The awakening of an advanced malignant cancer: an insult
to the mitochondrial genome, Biochim. Biophys. Acta (Sep 2 2011) [Epub ahead
of print].
[17] P.H. Reddy, T.P. Reddy, Mitochondria as a therapeutic target for aging and neuro-
degenerative diseases, Curr. Alzheimer Res. 8 (2011) 393–409.
[18] M.G. Ford, S. Jenni, J. Nunnari, The crystal structure of dynamin, Nature 477
(2011) 561–566.
[19] J.R. Friedman, L.L. Lackner, M. West, J.R. DiBenedetto, J. Nunnari, G.K. Voeltz, ER
tubules mark sites of mitochondrial division, Science 334 (2011) 358–362.
[20] P.H. Reddy, T.P. Reddy, M. Manczak, M.J. Calkins, U. Shirendeb, P. Mao, Dynamin-
related protein 1 and mitochondrial fragmentation in neurodegenerative dis-
eases, Brain Res. Rev. 67 (2011) 103–118.
[21] C.S. Palmer, L.D. Osellame, D. Stojanovski, M.T. Ryan, The regulation of mitochon-
drial morphology: intricate mechanisms and dynamic machinery, Cell. Signal. 23
(2011) 1534–1545.
[22] Y. Kageyama, Z. Zhang, H. Sesaki, Mitochondrial division: molecular machinery
and physiological functions, Curr. Opin. Cell Biol. 23 (2011) 427–434.
[23] M. Manczak, P. Mao, M.J. Calkins, A. Cornea, A.P. Reddy, M.P. Murphy, H.H. Szeto,
B. Park, P.H. Reddy, Mitochondria-targeted antioxidants protect against amyloid-
beta toxicity in Alzheimer's disease neurons, J. Alzheimers Dis. 20 (Suppl 2)
(2010) S609–S631.
[24] M.J. Calkins, M. Manczak, P. Mao, U. Shirendeb, P.H. Reddy, Impaired mitochon-
drial biogenesis, defective axonal transport of mitochondria, abnormal mitochon-
drial dynamics and synaptic degeneration in a mouse model of Alzheimer's
disease, Hum. Mol. Genet. 20 (2011) 4515–4529.
[25] P.H. Reddy, U.P. Shirendeb, Mutant huntingtin, abnormal mitochondrial dynam-
ics, defective axonal transport of mitochondria, and selective synaptic degenera-
tion in Huntington's disease, Biochim. Biophys. Acta 1822 (2012) 101–110.
[26] J. Wakabayashi, Z. Zhang, N. Wakabayashi, Y. Tamura, M. Fukaya, T.W. Kensler, M.
Iijima, H. Sesaki, The dynamin-related GTPase Drp1 is required for embryonic and
brain development in mice, J. Cell Biol. 186 (2009) 805–816.
[27] N. Ishihara, M. Nomura, A. Jofuku, H. Kato, S.O. Suzuki, K. Masuda, H. Otera, Y.
Nakanishi, I. Nonaka, Y. Goto, N. Taguchi, H. Morinaga, M. Maeda, R.
Takayanagi, S. Yokota, K. Mihara, Mitochondrial ﬁssion factor Drp1 is essential
for embryonic development and synapse formation in mice, Nat. Cell Biol. 11
(2009) 958–966.
[28] M. Manczak, T.S. Anekonda, E. Henson, B.S. Park, J. Quinn, P.H. Reddy, Mitochon-
dria are a direct site of A beta accumulation in Alzheimer's disease neurons: im-
plications for free radical generation and oxidative damage in disease
progression, Hum. Mol. Genet. 15 (2006) 1437–1449.
[29] B. Drew, C. Leeuwenburgh, Method for measuring ATP production in isolated mi-
tochondria: ATP production in brain and liver mitochondria of Fischer-344 rats
with age and caloric restriction, Am. J. Physiol. Regul. Integr. Comp. Physiol. 285
(2003) R1259–R1267.
[30] E.D. Hall, J.M. Bosken, Measurement of oxygen radicals and lipid peroxidation in
neural tissues, Curr. Protoc. Neurosci. (2009) Chapter 7:Unit 7.17 1–51.
[31] S.T. DeKosky, S.W. Scheff, Synapse loss in frontal cortex biopsies in Alzheimer's
disease: correlation with cognitive severity, Ann. Neurol. 27 (1990) 457–464.
[32] R.D. Terry, E. Masliah, D.P. Salmon, N. Butters, R. DeTeresa, R. Hill, L.A. Hansen, R.
Katzman, Physical basis of cognitive alterations in Alzheimer's disease: synapse
loss is the major correlate of cognitive impairment, Ann. Neurol. 30 (1991)
572–580.
[33] D.J. Selkoe, Alzheimer's disease is a synaptic failure, Science 298 (2002) 789–791.
[34] S.E. Folstein, Huntington's Disease, Johns Hopkins University Press, 1990.
[35] A. Montoya, B.H. Price, M. Menear, M. Lepage, Brain imaging and cognitive dys-
functions in Huntington's disease, J. Psychiatry Neurosci. 31 (2006) 21–29.
[36] C.A. Ross, S.J. Tabrizi, Huntington's disease: from molecular pathogenesis to clin-
ical treatment, Lancet Neurol. 10 (2011) 83–98.
